GlassScriptPhysician profile
Edgardo Benavides
NPI 1194919639
$20,281.02
in general payments reported to CMS, 2019-2025
49 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,493 · 2020: $2,016 · 2021: $2,961 · 2022: $4,086 · 2023: $3,580 · 2024: $1,692 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,725.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,778.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $2,510.64 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $2,143.58 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,804.13 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,364.71 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $886.43 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $768.87 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $678.01 | 2021-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.78 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $525.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $507.43 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $473.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $455.32 | 2023-2025 | |
| Esperion Therapeutics, INC. | $420.71 | 2020-2023 | Nexletol |
| Amarin Pharma, INC. | $413.38 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgardo Benavides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.